Identify potential failures earlier and inform alternate strategies to keep your program on track
Our Global Metabolomics Solution provides a high-resolution in-vivo view of your molecule’s impact on preclinical models to help identify potential clinical risks and plan mitigations before you invest in expensive and time-consuming FiH trials.
Build confidence in the safety and efficacy of your program prior to FiH
See a clearer view of off-target effects and potential toxicity earlier in development
Identify pre-clinical biomarkers of pharmacodynamics, safety and efficacy with high-levels of clinical translatability
In vivo biological screening to guide therapeutic strategy